Charge Heterogeneity Analysis of Rituximab Innovator and Biosimilar Monoclonal Antibodies

Recombinant monoclonal antibodies (mAbs) are important biotherapeutics with a wide range of diagnostic and clinical applications. Recently, biosimilar products are increasing in popularity in biopharmaceuticals. This study performs high-resolution separation of charge variants of innovator and biosimilar rituximab using an Agilent 1260 Infinity Bio-inert Quaternary LC, biocolumns, and an Agilent OpenLAB ChemStation Software tool.